文献速递免疫规划

巴拿马儿童接种1剂与2剂甲肝疫苗后8年和10年抗体持久性

Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama.
PubMed 文献 · Vaccine · 2020-11-22

该研究在巴拿马儿童接种1剂或2剂Havrix后第8年和第10年开展横断面血清学调查,评估抗HAV抗体血清阳性率和几何平均浓度。结果显示2剂组血清阳性率在8年和10年均高于1剂组,1剂组非劣效性未成立。

要点

  • 2剂组8年血清阳性率97.7%,10年96.3%。
  • 1剂组8年血清阳性率74.3%,10年71.9%。
  • 1剂对2剂的非劣效性未成立,组间差95%CI下限<-10%。

核心结论

  • 接种1剂Havrix的儿童在8年和10年时抗HAV抗体持久性低于2剂接种儿童。

研究设计与样本

  • 在接种后第8年和第10年开展两项独立横断面血清学调查,评估巴拿马国家免疫规划中1剂或2剂灭活甲肝疫苗(Havrix,GSK)接种儿童。
  • 第8年纳入600名儿童,第10年纳入599名儿童。

主要发现

  • 第8年血清阳性率:1剂组74.3%(95%CI:69.0;79.2),2剂组97.7%(95%CI:95.3;99.1)。
  • 第10年血清阳性率:1剂组71.9%(95%CI:66.4;76.9),2剂组96.3%(95%CI:93.5;98.2)。
  • 两次调查中1剂组抗体GMC均低于2剂组。

关键数值与推荐

  • 血清阳性定义为抗HAV抗体浓度≥15 mIU/mL。
  • 非劣效性未成立,因1剂减2剂血清阳性率差的95%CI下限<-10%。

临床怎么用

  • 在巴拿马儿童国家免疫规划中,2剂Havrix接种在8年和10年时抗体持久性优于1剂。

局限性

  • 需进一步研究确认拉丁美洲儿童接种后超过10年的抗体持久性和保护力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis A virus (HAV) remains a global public health concern, which is potentially growing in Latin America, due to an expected shift from high to intermediate endemicity levels. The use of HAV vaccines in pediatric national immunization programs (NIPs), either as a 2-dose or a 1-dose schedule, has been explored in Latin American countries; however, evidence demonstrating long-term protection in this population is limited in the region. We evaluated long-term antibody persistence following a 1-dose partial series and the recommended 2-dose schedule used in Panama's pediatric NIP. METHODS: Two independent cross-sectional serological surveys were conducted at year 8 (Y8) and Y10 following vaccination under the NIP with 1 or 2 doses of an inactivated HAV vaccine (Havrix, GSK). Seropositivity (anti-HAV antibody concentration ≥ 15 mIU/mL) rates and antibody geometric mean concentrations (GMCs) were assessed at each serosurvey. Non-inferiority of 1 dose versus 2 doses was also explored. RESULTS: This study (NCT02712359) included 600 and 599 children at Y8 and Y10 post-vaccination, respectively. Seropositivity rates were 74.3% (95% confidence interval [CI]: 69.0; 79.2) and 97.7% (95% CI: 95.3; 99.1) at Y8 and 71.9% (95% CI: 66.4; 76.9) and 96.3% (95% CI: 93.5; 98.2) at Y10, in the 1-dose and 2-dose groups, respectively. Antibody GMCs were lower in the 1-dose versus the 2-dose group in both surveys. Non-inferiority was not demonstrated since the lower limit of the 2-sided 95% CI for the between-group difference in seropositivity rates (1-dose minus 2-dose) was < -10%. CONCLUSION: Anti-HAV antibody persistence was observed in lower percentages of children receiving 1 dose versus 2 doses of Havrix, at 8 and 10 years post-vaccination in Panama. Further investigations are needed to confirm antibody persistence and conclude on the protection afforded beyond 10 years in the pediatric population in Latin America.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Juliao P, Abadia I, Welby S, et al. Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine. 2020. PMID: 33239226. doi:10.1016/j.vaccine.2020.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。